Mengis Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.59M Buy
70,364
+3,670
+6% +$174K 0.45% 61
2025
Q4
$3.39M Buy
66,694
+50,154
+303% +$2.56M 0.6% 45
2025
Q3
$918K Buy
+16,540
New +$968K 0.18% 110

Other funds holding NVO

Mengis Capital Management's NVO Position: Q1 2026 in Review

Mengis Capital Management increased its Novo Nordisk (NVO) stake by 5.5% in Q1 2026, buying an estimated $174K and bringing the position to 70,364 shares worth $2.59M. The position accounts for 0.45% of the portfolio, ranked #61.

Mengis Capital Management first reported a position in NVO in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.39M in Q4 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Mengis Capital Management held 70,364 shares of Novo Nordisk worth $2.59M as of Q1 2026.
  • Mengis Capital Management bought 3,670 Novo Nordisk shares in Q1 2026, an estimated $174K.
  • Novo Nordisk made up 0.45% of Mengis Capital Management's portfolio in Q1 2026, its #61 holding.
  • Mengis Capital Management first reported a position in Novo Nordisk in Q3 2025 and has held it in 3 quarters since.
  • Mengis Capital Management's Novo Nordisk position peaked at $3.39M in Q4 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.